Clinical Trials
44 trialsNCT06427811 2026-04-17
ASC4INDIA
Novartis
Phase 4 Completed
NCT04063215 2026-01-15
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy
Hope Biosciences Research Foundation
Phase 1/2 Completed
NCT03774082 2025-12-11
REACH 5
Novartis
Phase 2 Completed
NCT03790332 2025-10-21
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
Pharmacyclics LLC.
Phase 1/2 Completed
NCT03112603 2025-08-12
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Phase 3 Completed
NCT04795427 2025-04-18
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Novartis
Phase 2 Completed
NCT00457782 2024-04-25
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT01063907 2024-04-25
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT02743351 2023-02-08
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Fate Therapeutics
Phase 1/2 Completed
NCT01991184 2022-06-21
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
Genentech, Inc.
Phase 1 Completed
NCT01994382 2022-04-05
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Alexion Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02130557 2021-05-18
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
Phase 3 Completed
NCT01844765 2021-04-22
DIALOG
Novartis
Phase 2 Completed
NCT02334748 2020-05-19
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
Novartis
Phase 3 Completed
NCT02085798 2020-01-27
Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)
Celgene
Completed
NCT01578707 2019-12-18
RESONATEâ„¢
Pharmacyclics LLC.
Phase 3 Completed
NCT02164071 2019-11-18
GAH
Celgene
Completed
NCT01490632 2019-09-27
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company
Phase 2 Completed
NCT01107457 2019-09-24
A Study in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company
Phase 2 Completed
NCT02891551 2019-07-24
OCEAN
Celgene
Completed
NCT02195869 2019-07-11
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
Pharmacyclics LLC.
Phase 1/2 Completed
NCT01815424 2019-04-16
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT02908347 2019-01-23
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
MetrioPharm AG
Phase 2 Completed
NCT01186744 2018-12-26
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01241591 2018-12-26
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01313689 2018-11-08
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Novartis
Phase 3 Completed
NCT00513656 2018-10-23
A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain
Mundipharma Research GmbH & Co KG
Phase 2 Completed
NCT00742144 2017-11-17
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 1 Completed
NCT01677780 2017-07-07
An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
Hoffmann-La Roche
Phase 1 Completed
NCT02321397 2016-11-04
To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain
Mundipharma Research GmbH & Co KG
Phase 2/3 Completed
NCT02461316 2016-11-02
Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Completed
NCT01559844 2016-07-27
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Gilead Sciences
Phase 2 Completed
NCT01680991 2016-04-25
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
Hoffmann-La Roche
Phase 1 Completed
NCT00802841 2015-11-16
LASOR
Novartis
Phase 3 Completed
NCT01519089 2015-08-13
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
Pfizer
Phase 3 Completed
NCT00431873 2015-07-01
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Mirati Therapeutics Inc.
Phase 2 Completed
NCT01276639 2014-09-19
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01309737 2014-09-19
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT00328198 2014-03-13
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Sanofi
Phase 2 Completed
NCT01149668 2013-06-19
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
Pharmacyclics LLC.
Phase 1 Completed
NCT00078234 2011-11-07
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia
Genta Incorporated
Phase 1/2 Completed
NCT00825487 2011-10-19
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed
NCT00103701 2011-04-14
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
Bristol-Myers Squibb
Phase 1 Completed
NCT00021749 2009-11-13
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia
Genta Incorporated
Phase 1/2 Completed